Teva Photo: Sivan Faraj Credit Suisse cuts Teva's target price again

Credit Suisse has now lowered the price to $14 per share from $18, having cut the price from $20 just three weeks ago.

Perrigo Yeruham  photo: Netanel Levi and Patrick Mazuz Perrigo guarantees 5 years Israel operations in Yeruham

The workers in the Yeruham plant will also receive bonuses and pay hikes under the agreement signed with Perrigo's management.

Anti-depressants Photo: Shutterstock Digital therapeutics co Happify teams with Sanofi

Happify combines digital therapeutics with drug treatment.

Gilad Japhet Israeli genealogy co MyHeritage to launch DNA health test

The test provides a new dimension of genetic insight with comprehensive health reports that can empower future health and lifestyle choices.

Vincent Tchenguiz Photo: Christopher Ratcliffe Vincent Tchenguiz to invest $7m in BioProtect

BioProtect's product protects healthy tissue from radiation during cancer treatment.

Yaakov Litzman  photo: Alex Kolomoisky, Yediot Easier user rules prospect boosts cannabis stocks

Deputy Minister of Health Yaakov Litzman announced that a license would no longer be required to use cannabis for certain indications.

Ron Babecoff and Tami Ben-Yedidya aMoon expands investment in BiondVax

The life sciences venture capital fund could become the controlling shareholder in universal flu vaccine developer Biondvax after the company's rights issue.

Dr. Yacov Geva Photo: Tamar Matsafi Israeli diagnostics co G Medical set for Nasdaq offering

The Israeli company has developed two products: a heart diagnostic device connected to a smartphone and a sticker for monitoring patients in hospital beds

Teva Photo: ASAP Creative Shutterstock S&P: Teva faces greatest liability in US antitrust suit

S&P Global is not changing its rating for Teva's debt at present.

Warren Buffett Photo: Reuters Kevin Lamarque Warren Buffett loses nearly $300m on Teva

With 43 million shares in the Israeli pharmaceutical company, Berkshire Hathaway has lost $283 million on its Teva stake this year.

Kare Schultz Photo: Shlomi Yosef Little chance of Teva CEO seeing share price bonus

Kare Schultz received millions of dollars of blocked shares, which he will receive if the share price reaches a certain level by November 2020.

Teva Photo: Sivan Faraj Teva continues to tumble amid price fixing charges

HSBC estimates Teva will face a $3 billion fine and has cut the Israeli pharmaceutical company's share target price to $10.

Prof. Shulamit Levenberg Photo: Rami Chelouche Israeli researcher offers hope in overcoming paralysis

By implanting engineered tissue from stem cells taken from the gums, the Technion's Prof. Shulamit Levenberg provides new hope for people with spinal column injuries.

Teva Photo: Sivan Faraj Teva to stand trial in US opioids affair

A judge in Oklahoma rejected an attempt by Teva and Johnson & Johnson to have charges against them dismissed.

Barak Rosen  photo: PR Barak Rosen, Luzon investing NIS 17.5m in Panaxia

The investment is in stock exchange shell Herodium, into which cannabis company Panaxia Israel will be merged.

Check Cap Photo: Company website Mayo Clinic joins Check Cap pilot study

Check Cap's C-Scan system is an ingestible capsule for the detection of precancerous polyps.

Cannabis plant Photo: Shutterstock Cannabit to sell cannabis to Panaxia if it can

Assuming it obtains all of the necessary permits, Cannabit's revenue from the agreement will be NIS 30 million.

Teva CFO Michael McClellan Photo: Company website Teva CFO: We'll defend ourselves vigorously

Speaking at an Oppenheimer conference, Teva's Mike McClellan said the price-fixing allegations in the US were not new, and went on to describe the company's growth engines.

Teva Photo: ASAP Creative Shutterstock Teva faces price-fixing claim in US

44 US states have filed a lawsuit alleging that Teva conspired with other companies to raise prices of generic drugs by as much as 1,000%.

Prof. Irad Ben-Gal  photo: Eyal Izhar The times they are a-changing us

Prof. Irad Ben-Gal talks to "Globes" about dual digital and physical existence, and other ways technology will challenge our present assumptions about human life.

Dr. Anda Baharav Photo: Shlomi Yosef Sleeprate's app and cognitive therapy end insomnia

At 55, Dr. Anda Baharav left her work as a pediatrician to found a startup that provides personalized treatment for sleep disorders.

Prof. Tal Dvir Photo: Eyal Izhar "Barriers are more regulatory than technological"

Having 3D printed a heart, Tel Aviv University's Prof. Tal Dvir says in principle, he can regenerate any organ in the body.

Tel Aviv traffic jam  photo: Eyal Izhar The new government's economic challenges

Transport, energy and healthcare are three areas where big decisions loom, and determination will be needed to carry them out.

Cannabis plant Photo: Shutterstock Israel's cannabis reform: Hopes and fears

"Globes" examines what the pioneering medical cannabis reform, due to come into effect after the election, will mean for patients, doctors, and all concerned.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018